Buddy Lyons
Value, long/short equity, contrarian, growth

BioMarin: All Drivers Will Soon Be In Place For Explosive Growth - At Least 50% Upside

We have followed BMRN since 2001 when we launched coverage at $3. Under the leadership of Jean-Jacques Bienaime since 2005 the company has launched four products treating orphan diseases and has built an enviable pipeline. The stock is up almost 900% over the past 10 years, even though the company has yet to become profitable. The promise of profitability for BMRN has been elusive, but elusive for a reason. The company has built one of the deepest pipelines in the industry and has dramatically increased R&D to move that pipeline forward as quickly as possible. R&D as a percent of sales increased from 39% to 64% from 2010 to 2013. In dollars, that's a doubling of R&D while revenue increased...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
FREESA PRO MEMBERS
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details